The PI3K/Akt signaling, an important pathway downstream of EGFR, has been demonstrated that aberrant activation of it could promote TKI resistance in NSCLC (Toulany and Rodemann, 2015). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.